Shares of Hims & Hers closed up 23% on Tuesday, while Novo Nordisk's stock closed up 4%. The Danish drugmaker is racing to capture more patients now that many compounding pharmacies are legally ...

Online telehealth company Hims and Hers Health is launching its weight-loss membership and treatment plans in the United ...

In a crowded GLP-1 race dominated by giants, retail traders are siding with Novo Nordisk for the long haul, according to a 1,100-vote Stocktwits poll that pushes Hims & Hers, Viking Therapeutics and ...

One of largest U.S. telehealth providers expects to ride wave of exploding demand for weight-loss drug semaglutide when it ...

Online telehealth company Hims and Hers Health HIMS.N is launching its weight-loss membership and treatment plans in the UK ...

In a strategic pivot, the company has launched its weight-loss program in the United Kingdom. There, Hims & Hers is offering legitimate, branded medications—Novo Nordisk's Wegovy and Eli Lilly's ...

For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

Hims & Hers Health reported strong 3Q25 revenue growth of 49% YoY, despite a GAAP EPS miss and shares falling post-earnings. HIMS is expanding its offerings, including testosterone and potential ...

The move into the UK weight-loss category has been facilitated by the acquisition earlier this year of Zava, a London-based ...

Novo Nordisk (NYSE: NVO) says it will collaborate with WeightWatchers to expand access to Novo’s Wegovy GLP-1 diet drug beginning on July 1. WeightWatchers customers will be able to use CenterWell ...

Since my last update, Hims & Hers Health, Inc. stock has fallen by >25% before recovering all of its losses. Recent news flow has been mixed, with some insider selling and criticism of some business ...